Hepatic steatosis, often triggered by non-alcoholic fatty liver disease (NAFLD), is a leading cause of liver dysfunction ...

More than 100 million Americans struggle with obesity and related metabolic disorders, a staggering number with widespread ...

Solute carrier (SLC) family transporters are crucial transmembrane proteins responsible for transporting various molecules, ...

NewsMedical speaks with CN Bio about the translatability between in vitro organ-on-a-chip (OOC) models, microphysiological ...

as cell membrane stabilisers and permeability regulators that prevent hepatotoxic agents from entering hepatocytes; (iii) as promoters of ribosomal RNAsynthesis, stimulating liver regeneration ...

Hepatic steatosis, often triggered by non-alcoholic fatty liver disease (NAFLD), is a leading cause of liver dysfunction globally, affecting ...

Assembly Biosciences (ASMB) announced that the first participant has been dosed in the Phase 1a trial of ABI-6250, the company’s orally ...

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is a global health ...

YolTech Therapeutics reports positive clinical data for YOLT-203, an in vivo gene editing therapy for primary hyperoxaluria type 1: Shanghai, China Wednesday, February 26, 2025, 1 ...

The global organoids market is on the cusp of unprecedented expansion, with projections indicating a meteoric rise to USD 1,306.4 million by 2024. This robust growth trajectory is expected to continue ...

Phase 1a study will evaluate single and multiple ascending doses of ABI-6250 in healthy participants with data expected in Q3 2025 –– Biomarker ...